| Popis: |
ObjectiveTo evaluate the clinical efficacy of transarterial chemoembolization (TACE) combined with microwave coagulation therapy (MCT) in the treatment of advanced liver cancer and to provide a more convincing basis for the clinical application of this therapy. MethodsA search was performed using Cochrane Library, PubMed, Em-base, CBM, CNKI, VIP WanFang Data as well as other sources to collect randomised controlled trials (RCTs) of TACE combined with MCT in the treatment of advanced primary liver cancer. The literature was selected according to inclusion criteria. The quality of included studies was assessed according to Cochrane review criteria. A Meta-analysis was performed on homogeneous studies using RevMan 5.0. The patients receiving TACE combined with MCT were compared with those receiving TACE alone in terms of 0.5-year, 1-year, and 2-year survival rates and negative conversion rate of alpha-fetoprotein (AFP). ResultsA total of 12 RCTs involving 872 cases were included in the analysis. Compared with those receiving TACE alone, the patients receiving TACE combined with MCT had a significantly higher 0.5-year survival rate (OR=7.21, 95% CI: 1.92-2708, P=0.003), a significantly higher 1-year survival rate (OR=4.47, 95% CI:3.14-6.36, P＜0.000 01), a significantly higher 2-year survival rate (OR=3.66, 95% CI:2.45-4.84, P＜0.000 01), and a significantly higher negative conversion rate of AFP (OR=2.65, 95% CI:1.73-4.07, P＜0.000 1). ConclusionCompared with TACE alone, TACE combined with MCT can produce better short-term and long-term treatment outcomes and significantly improve the survival rate in patients with unresectable advanced liver cancer, according to the meta-analysis. This combination therapy might be clinically effective, but which needs to be confirmed by a large number of high-quality controlled clinical trials. |
